Corporate News 14-Jun-24
Lupin's Nagpur facility successfully clears USFDA audit
Lupin announced that the United States Food and Drug Administration (U.S. FDA) has completed an inspection of its Injectable facility in Nagpur, India. The inspection of the facility was carried out from 10 June to 13 June 2024, and concluded with zero 483 observations.
Previous News
Lupin launches Ipratropium Bromide Nasal Solution in US market
( Corporate News - 04-Jul-25 16:05 )
Lupin launches generic version of anticholinergic medication Ipratropium bromide in United States
( Hot Pursuit - 04-Jul-25 15:29 )
Lupin gets USFDA nod for Loteprednol Etabonate Ophthalmic Gel
( Hot Pursuit - 02-Jul-25 12:53 )
Lupin carves-out its LupinLife Consumer Healthcare
( Corporate News - 01-Jul-25 18:39 )
Lupin receives USFDA approval for Loteprednol Etabonate Ophthalmic Gel
( Corporate News - 01-Jul-25 18:37 )
Lupin update on transfer of its OTC biz to LUPINLIFE Consumer Healthcare
( Corporate News - 30-Jun-25 18:54 )
Lupin launches Prucalopride tablets in U.S. market
( Hot Pursuit - 26-Jun-25 13:12 )
Lupin launches Prucalopride Tablets in US market
( Corporate News - 26-Jun-25 13:05 )
Lupin receives USFDA approval for generic Prucalopride tablets
( Hot Pursuit - 25-Jun-25 13:47 )
Lupin receives USFDA approval for Prucalopride Tablets
( Corporate News - 25-Jun-25 13:29 )
Lupin allots 20,653 equity shares under ESOP
( Corporate News - 24-Jun-25 19:04 )
Other Stories
Paradeep Parivahan to conduct board meeting
05-Jul-25 17:25
Futura Polyesters to table results
05-Jul-25 17:24
Oswal Pumps schedules board meeting
05-Jul-25 17:24
Cupid to discuss results
05-Jul-25 17:24
Ashnisha Industries schedules board meeting
05-Jul-25 17:24
BSL AGM scheduled
05-Jul-25 17:24
IFB Industries to convene board meeting
05-Jul-25 17:23
IFB Industries schedules AGM
05-Jul-25 17:23
Shree Steel Wire Ropes to hold board meeting
05-Jul-25 17:23
Sellwin Traders to announce Quarterly Result
05-Jul-25 17:23
Back
Top
